This extension module explores ADHD across the lifespan, examining its core symptoms, comorbidities, and contributing factors. Topics include a review of endocannabinoid influence on neurotransmitters and behaviour; associated comorbidities and complex cannabis use patterns; specific cannabinoid benefits and pitfalls in managing ADHD; 
risks of therapy including dependence and  cannabis use disorder. 

Learners will be guided on evidence-informed prescribing plans and applying strategies for safe initiation, 
monitoring, and titration of cannabinoid therapy with a focus on patient-centred care. 

A Case study will be presented to develop and assess clinical reasoning and practice management skills, identify knowledge gaps, and provide a framework for clinical supervision and feedback.

Learning Outcomes

After completing this activity pharmacists should be able to:

1. Identify the core symptoms, comorbidities and contributing factors associated with ADHD across the lifespan.

2. Evaluate the risks and usage pattern of cannabis, (illicit and medicinal) in the ADHD population.

3. Describe the role of the endocannabinoid system (ECS) in ADHD and comorbid conditions.

4. Apply your knowledge to safely counsel patients on side effects, medication interactions and risk for cannabis use disorder.

5. Differentiate and compare risks of various dosage forms and cannabinoid ratios in the setting of ADHD.

Feedback evaluation forms are provided at the end of each module.